The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of Kansas

Johns Hopkins University

The University of North Carolina at Chapel Hill

Northwestern University

Pontificia Universidad Catòlica De Chile

The United States of America, As Represented by Th

Pontifica Universidad Catoclica De Chile

Marc Ferrer

Juan Jose Marugan

Noel Terrence Southall

Xin Hu

Kevin Frankowski

David Robert Sibley

R Benjamin Free

Frank John Schoenen

Warren S Weiner

Ravit Boger

Joseph Perry Steiner

Jeffrey Aubé

Amy Elizabeth Moritz

Alejandra Alvarez

Daniel C Talley

Rommy M Von Bernhardi

Andres Dulcey Garcia

Barbara S Slusher

Wei Ping Zheng

Michael Baltezor

Jingbo Xiao

Christopher R Dextras

Andres E Dulcey

Silvana Zanlungo

Samarjit Patnaik

Chen Wang

Sui Huang

Camilo Rojas

Norman J Haughey

Gaurav Sharma

Prashi Jain

Kelin Li

Ajit G Thomas

John Haslam

Zongyi Hu

Altea Rocchi

Shanshan He

Yuchi Chen

Udo Rudloff

Congcong He

Melvin L DePamphilis

Tsanyang Liang

Ajit Roy

Serguei Kozlov

John C Braisted

Jennie L Conroy

Kathryn D Luderman

Jeffrey AubÉ

Wei Zheng

Kevin J Frankowski

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as 'c-Abl'). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.

Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof

Selective D3 dopamine receptor agonists and methods of their use

Methods for treating one or more diseases associated with neutral sphingomyelinase 2 (nSMase2) in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of 2,6-dimethoxy-4-(5-phenyl-4-thiophen-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) or a pharmaceutically acceptable salt thereof, are disclosed.

2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a small molecule inhibitor of neutral sphingomyelinase 2 (nSMase-2) for the treatment of neurodegenerative and oncologic diseases

C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R, R, R, and Rare defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

Selective Ddopamine receptor agonists and methods of their use

Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: wherein R, R, and Rare as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.

Autophagy modulators for use in treating cancer

The invention provides a compound of formula (I): wherein R, R, R, and Rare as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof. 

Autophagy inducers for treatment of CNS conditions

Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers. 

Heterocyclic compounds and methods of use thereof

The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine Dreceptor. The variables R-R, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia. 

11-OXO-10,11-dihydrodibenzo[B,F][1,4]thiazepine S-oxide derivatives and their use as dopamine D2 receptor antagonists

Growing community of inventors

Potomac, MD, United States of America

Marc Ferrer